MEDS VS BTTX Stock Comparison

Performance

MEDS
10/100

MEDS returned -41.09% in the last 12 months. Based on SPY's performance of -13.95%, its performance is below average giving it a score of 10 of 100.

BTTX
10/100

BTTX returned -88.73% in the last 12 months. Based on SPY's performance of -13.45%, its performance is below average giving it a score of 10 of 100.

Technicals

MEDS
36/100

MEDS receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

BTTX
36/100

BTTX receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

Earnings

MEDS
10/100

MEDS has missed earnings 9 times in the last 20 quarters.

BTTX
33/100

BTTX has missed earnings 3 times in the last 20 quarters.

Profit

MEDS
22/100

Out of the last 20 quarters, MEDS has had 6 profitable quarters and has increased their profits year over year on 2 of them.

BTTX
10/100

Out of the last 12 quarters, BTTX has had 1 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

MEDS
52/100

MEDS has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

BTTX
31/100

BTTX has had a lower than average amount of volatility over the last 12 months giving it a score of 31 of 100.

All score calculations are broken down here to help you make more informed investing decisions

TRxADE HEALTH, Inc. Common Stock Summary

Nasdaq / MEDS

Healthcare

Medical - Pharmaceuticals

TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.

Better Therapeutics, Inc. Common Stock Summary

Nasdaq / BTTX

Healthcare

Biotechnology

Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.

Power up your portfolio